ASTRAZEN - Astrazeneca Phar

📊 NSE: ASTRAZEN 🏢 Pharmaceuticals - Multinational 📅 Last Updated: 12/13/2025 18:40

💰 Financial Performance

Revenue Growth by Segment

Total revenue grew 29% YoY to INR 1,300 Cr. Product sales crossed INR 1,000 Cr for the first time. Q1 FY25 revenue grew 45% YoY excluding Lynparza, and 8% on a quarter-on-quarter basis.

Geographic Revenue Split

Primarily focused on the Indian pharmaceutical market, which is valued at INR 2,16,091 Cr (USD 26.04 billion). Specific % split between domestic and overseas markets not disclosed.

Profitability Margins

Gross margins have declined in the last two quarters of FY24 and Q1 FY25. This is attributed to a shift toward becoming a specialist organization focusing on trading products (imported from parent entities) rather than local manufacturing.

EBITDA Margin

Core profitability metrics not explicitly disclosed, but EPS grew 63% YoY to INR 64.60.

Capital Expenditure

Not disclosed in available documents, though the company is exiting its Bangalore manufacturing site, resulting in a Q1 FY25 write-off of INR 57 Cr.

⚙️ Operational Drivers

Raw Materials

Traded goods and raw materials for pharmaceutical formulations in Oncology, Cardiovascular, Diabetes, and Respiratory therapies.

Import Sources

United Kingdom and Sweden.

Key Suppliers

AstraZeneca UK Limited (INR 831.08 Cr in purchases) and AstraZeneca AB, Sweden (INR 295.28 Cr in purchases).

Capacity Expansion

The company is currently exiting its Bangalore manufacturing site as part of a strategic review of its Global Manufacturing and Supply Network and is exploring a buyer for the site.

Raw Material Costs

Total related party purchases of raw materials and traded goods amounted to approximately INR 1,126.36 Cr in FY25. Procurement is conducted at arm's length.

Manufacturing Efficiency

Maintained zero Lost Time Injuries (LTI) and seamless supply to patients despite the planned exit from the Bangalore facility.

📈 Strategic Growth

Expected Growth Rate

30%

Growth Strategy

Strategy focused on 'Growth through Innovation' by bringing innovative medicines faster to India and improving patient access. This includes 9 regulatory approvals in FY24 and a strategic alliance with Sun Pharma to leverage their chronic therapy coverage.

Products & Services

Medicines for Oncology, Cardiovascular, Renal, Metabolism (CVRM), Diabetes, Respiratory, and Rare Diseases.

Brand Portfolio

Tagrisso, Imfinzi, Brilinta, Lynparza, Forxiga, Crestor, Enhertu, Seloken XL, Zoladex 10.8, Betaloc, Fasenra, Xigduo, Symbicort.

New Products/Services

9 regulatory approvals achieved in FY24; ongoing focus on the global pipeline to reach parent company's USD 80 billion target by 2030.

Market Expansion

Expanding reach in India through a strategic alliance with Sun Pharmaceutical Industries Limited to leverage their strong presence in chronic therapies.

Market Share & Ranking

Among the top 10 fastest-growing pharma companies in India; improved 3 ranks in FY24.

Strategic Alliances

Sun Pharmaceutical Industries Limited (distribution/reach), Mankind Pharma (recognition of deferred revenue/amortization).

🌍 External Factors

Industry Trends

Indian pharma market grew 7.6% to INR 2,16,091 Cr. MNCs grew 6.05% while Indian companies grew 7.9%. The market is largely out-of-pocket and fragmented.

Competitive Landscape

Highly competitive and fragmented; Indian companies hold an 83% market share by value.

Competitive Moat

Moat is built on a strong innovation pipeline from the parent company and a leading position in high-growth segments like Oncology (Tagrisso sales of INR 319.9 Cr).